The Impact of Intratumoral Bacterial Response to Vaccine Therapy in Cancer Treatment
4 affiliations
- 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
- 2Newish Biological R&D Center, Wuxi 214122, China
- 3State Key Laboratory of Elemento-Organic Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
- 4Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Abstract
Therapeutic Human papillomavirus (HPVs) vaccines are designed to enhance the immunogenicity of HPV and promote the elimination of tumor cells effectively. Mounting evidence implies that tumor-resident microbiomes may influence therapeutic outcomes through immune modulation. In this study, we evaluated whether the intratumoral microbiota affects the efficacy of the therapeutic HPV vaccine. We analyzed RNA sequencing data from tumor tissues of C57BL/6N female mice treated with a DNA vaccine incorporating HPV16 E6/E7 antigens fused with the chemokine CCL11. Microbial community data were acquired using the PathSeq bioinformatics pipeline. Alpha diversity was estimated using the Shannon index and the number of observed taxonomic features, while beta diversity was assessed via principal coordinate analysis (PCoA) based on Bray–Curtis distance. Linear discriminant analysis Effect Size (LEfSe) analysis was performed to identify differentially abundant microbial taxa. Immune cell infiltration was characterized using the xCell deconvolution method. The analysis revealed significant divergence in both the alpha- and beta-diversity metrics of intratumoral microbiota, associated with treatment responsiveness. Vaccinated groups exhibited enriched abundances of the phyla Proteobacteria, together with a concomitant reduction in Firmicutes and Actinobacteria, and were associated with a positive response to cancer immunotherapy. Additionally, intratumoral microbiome composition and diversity correlated with the increased infiltration of CD8+ T cells, natural killer T (NKT) cells, and myeloid cells. This study identifies intratumoral microbiota remodeling as a key feature of therapeutic HPV vaccine response. The observed coordination between bacterial signatures and immune cell infiltration is associative and raises the hypothesis that intratumoral bacteria may modulate, rather than drive, antitumor immunity. These findings support the development of intratumoral microbiota profiling and highlight the potential for microbiota-targeted strategies to enhance cancer immunotherapy efficacy.
Related
- Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
- Early sputum bacterial load dynamics predict treatment response in multidrug-resistant/rifampicin-resistant tuberculosis: A multicenter prospective cohort study
- Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis
- Pre-Treatment CD44 and CD47 Expression and Pathological Complete Response After Neoadjuvant Therapy in Breast Cancer: An Exploratory Single-Center Study
- Intratumoral co-activation of ERV transcription and RNA virus-sensing is associated with radiotherapy-induced immune response and abscopal effect
BibTeX
@article{wang2026impact,
title = {{The Impact of Intratumoral Bacterial Response to Vaccine Therapy in Cancer Treatment}},
author = {Yu Wang and Zhong-Jie Sun and Hai-Long Qi and Di Zhao and Xiao-Dong Xing and Jian-Dong Jiang and Tian-Le Gao},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219663},
url = {https://www.mdpi.com/1422-0067/27/21/9663},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Impact of Intratumoral Bacterial Response to Vaccine Therapy in Cancer Treatment
AU - Yu Wang
AU - Zhong-Jie Sun
AU - Hai-Long Qi
AU - Di Zhao
AU - Xiao-Dong Xing
AU - Jian-Dong Jiang
AU - Tian-Le Gao
PY - 2026
DA - 2026/10/28
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219663
UR - https://www.mdpi.com/1422-0067/27/21/9663
AB - Therapeutic Human papillomavirus (HPVs) vaccines are designed to enhance the immunogenicity of HPV and promote the elimination of tumor cells effectively. Mounting evidence implies that tumor-resident microbiomes may influence therapeutic outcomes through immune modulation. In this study, we evaluated whether the intratumoral microbiota affects the efficacy of the therapeutic HPV vaccine. We analyzed RNA sequencing data from tumor tissues of C57BL/6N female mice treated with a DNA vaccine incorporating HPV16 E6/E7 antigens fused with the chemokine CCL11. Microbial community data were acquired using the PathSeq bioinformatics pipeline. Alpha diversity was estimated using the Shannon index and the number of observed taxonomic features, while beta diversity was assessed via principal coordinate analysis (PCoA) based on Bray–Curtis distance. Linear discriminant analysis Effect Size (LEfSe) analysis was performed to identify differentially abundant microbial taxa. Immune cell infiltration was characterized using the xCell deconvolution method. The analysis revealed significant divergence in both the alpha- and beta-diversity metrics of intratumoral microbiota, associated with treatment responsiveness. Vaccinated groups exhibited enriched abundances of the phyla Proteobacteria, together with a concomitant reduction in Firmicutes and Actinobacteria, and were associated with a positive response to cancer immunotherapy. Additionally, intratumoral microbiome composition and diversity correlated with the increased infiltration of CD8+ T cells, natural killer T (NKT) cells, and myeloid cells. This study identifies intratumoral microbiota remodeling as a key feature of therapeutic HPV vaccine response. The observed coordination between bacterial signatures and immune cell infiltration is associative and raises the hypothesis that intratumoral bacteria may modulate, rather than drive, antitumor immunity. These findings support the development of intratumoral microbiota profiling and highlight the potential for microbiota-targeted strategies to enhance cancer immunotherapy efficacy.
SN - 1422-0067
ER -